Literature DB >> 23585588

Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement.

Francesco Locatelli1, Peter Bárány, Adrian Covic, Angel De Francisco, Lucia Del Vecchio, David Goldsmith, Walter Hörl, Gerard London, Raymond Vanholder, Wim Van Biesen.   

Abstract

Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) group has produced comprehensive clinical practice guidelines for the management of anaemia in CKD patients. These guidelines addressed all of the important points related to anaemia management in CKD patients, including therapy with erythropoieis stimulating agents (ESA), iron therapy, ESA resistance and blood transfusion use. Because most guidelines were 'soft' rather than 'strong', and because global guidelines need to be adapted and implemented into the regional context where they are used, on behalf of the European Renal Best Practice Advisory Board some of its members, and other external experts in this field, who were not participants in the KDIGO guidelines group, were invited to participate in this anaemia working group to examine and comment on the KDIGO documents in this position paper. In this article, the group concentrated only on those guidelines which we considered worth amending or adapting. All guidelines not specifically mentioned are fully endorsed.

Entities:  

Keywords:  anaemia; chronic kidney disease; erythropoiesis stimulating agents; iron; mortality

Mesh:

Year:  2013        PMID: 23585588     DOI: 10.1093/ndt/gft033

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  119 in total

Review 1.  Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?

Authors:  Francesco Locatelli; Lucia Del Vecchio
Journal:  J Nephrol       Date:  2017-07-17       Impact factor: 3.902

2.  Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.

Authors:  Francesco Locatelli; Thierry Hannedouche; Steven Fishbane; Zoe Morgan; Delphine Oguey; William B White
Journal:  Clin J Am Soc Nephrol       Date:  2019-08-16       Impact factor: 8.237

Review 3.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis.

Authors:  Pei Yin; Yan Song; Jijun Li
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

5.  Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study.

Authors:  Aleix Cases; José Portolés; Jordi Calls; Alberto Martinez-Castelao; María Antonia Munar; Alfonso Segarra
Journal:  Int Urol Nephrol       Date:  2014-08-14       Impact factor: 2.370

6.  Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.

Authors:  Edouard R Martin; Mark T Smith; Bradley J Maroni; Qing C Zuraw; Emil M deGoma
Journal:  Am J Nephrol       Date:  2017-03-25       Impact factor: 3.754

7.  Intravenous iron administration strategies and anemia management in hemodialysis patients.

Authors:  Wieneke M Michels; Bernard G Jaar; Patti L Ephraim; Yang Liu; Dana C Miskulin; Navdeep Tangri; Deidra C Crews; Julia J Scialla; Tariq Shafi; Stephen M Sozio; Karen Bandeen-Roche; Courtney J Cook; Klemens B Meyer; L Ebony Boulware
Journal:  Nephrol Dial Transplant       Date:  2017-01-01       Impact factor: 5.992

Review 8.  Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology.

Authors:  Vincenzo Bellizzi; Giuseppe Conte; Silvio Borrelli; Adamasco Cupisti; Luca De Nicola; Biagio R Di Iorio; Gianfranca Cabiddu; Marcora Mandreoli; Ernesto Paoletti; Giorgina B Piccoli; Giuseppe Quintaliani; Maura Ravera; Domenico Santoro; Serena Torraca; Roberto Minutolo
Journal:  J Nephrol       Date:  2016-08-27       Impact factor: 3.902

9.  Cumulative iron dose and resistance to erythropoietin.

Authors:  A Rosati; C Tetta; J I Merello; I Palomares; R Perez-Garcia; F Maduell; B Canaud; P Aljama Garcia
Journal:  J Nephrol       Date:  2014-08-05       Impact factor: 3.902

Review 10.  The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.

Authors:  Kimberly Zumbrennen-Bullough; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-11-13       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.